Par Pharmaceutical Companies Reaches New 52-Week High (PRX)

NEW YORK ( TheStreet) -- Par Pharmaceutical Companies (NYSE: PRX) hit a new 52-week high Wednesday as it is currently trading at $37.24, above its previous 52-week high of $37.20 with 111,734 shares traded as of 1:38 p.m. ET. Average volume has been 412,700 shares over the past 30 days.

Par Pharmaceutical Companies has a market cap of $1.31 billion and is part of the health care sector and drugs industry. Shares are up 9.9% year to date as of the close of trading on Tuesday.

Par Pharmaceutical Companies, Inc., through its subsidiary, Par Pharmaceutical, Inc. engages in developing, licensing, manufacturing, marketing, and distributing generic and branded drugs in the United States.

TheStreet Ratings rates Par Pharmaceutical Companies as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Par Pharmaceutical Companies Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Global Stocks Rebound But US-China Trade War Concerns Keep Investors on Edge

Global Stocks Rebound But US-China Trade War Concerns Keep Investors on Edge

Stocks Rise, GE Dropped From the Dow, Starbucks, Oracle - 5 Things You Must Know

Stocks Rise, GE Dropped From the Dow, Starbucks, Oracle - 5 Things You Must Know

Starbucks Slides After 'Unacceptable' Performance Leads to U.S. Store Closures

Starbucks Slides After 'Unacceptable' Performance Leads to U.S. Store Closures

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI